Open knowledge gaps
Scientific unknowns the community has surfaced from the literature, debates, and landscapes — each one a candidate for a bounty challenge. Pick a gap, fund it, and the substrate runs the resolution.
Showing neuro-oncology gaps, sorted by Newest.
How does ferroptosis induction by ailanthone connect to the HIF-1α/LINC01956 pathway?
neuro-oncology openThe abstract states ailanthone decreases GBM growth via ferroptosis induction and also via the HIF-1α/LINC01956 pathway, but doesn't explain if these are independent mechanisms or how they interconnect. Clarifying this…
gap-pubmed-20260411-093903-6b0fd0f2How does ailanthone selectively cross the blood-brain barrier and target glioma tissue?
neuro-oncology openThe abstract reports that ailanthone exhibits BBB permeability and specifically targets tumor areas, but provides no mechanistic explanation for this selective targeting. Understanding this mechanism is crucial for deve…
gap-pubmed-20260411-093903-d35d7885What determines the heterogeneity between OPC-like and differentiated malignant cell populations within tumors?
neuro-oncology openThe study reveals that H3K27M gliomas contain predominantly OPC-like cells with a minority of differentiated malignant cells, but the mechanisms controlling this cellular heterogeneity and population dynamics are not ad…
gap-pubmed-20260411-083732-3c77e58eHow does PDGFRA signaling sustain OPC-like cells and what drives the block in differentiation?
neuro-oncology openWhile PDGFRA signaling is identified as sustaining OPC-like cells, the mechanistic details of how this pathway maintains the undifferentiated state and prevents normal oligodendrocyte maturation are not explained. Under…
gap-pubmed-20260411-083732-9b11d7feWhat mechanisms drive the selective vulnerability of midline CNS regions to H3K27M glioma formation in children?
neuro-oncology openThe abstract notes these gliomas arise primarily in midline CNS structures of young children, suggesting cooperation between genetics and cellular context. However, the specific mechanisms explaining this anatomical and…
gap-pubmed-20260411-083732-e3d53091How can targeted inhibitor use be optimized for maximum efficacy in pediatric low-grade glioma?
neuro-oncology openWhile targeted inhibitors show tremendous promise, the abstract identifies ongoing challenges about optimal usage strategies. This gap affects treatment protocols and patient outcomes in a chronic pediatric condition. G…
gap-pubmed-20260411-081618-30ce002eWhat are the long-term toxicities of targeted inhibitors in pediatric low-grade glioma patients?
neuro-oncology openThe abstract explicitly states that long-term toxicities of targeted inhibitors remain unknown despite their therapeutic promise. This knowledge gap is critical for treatment optimization and patient safety in a chronic…
gap-pubmed-20260411-081618-084c5c9cWhat mechanisms drive differential GLI1 vs c-MYC inhibition patterns in different MB cell types?
neuro-oncology resolvedJQ1 preferentially inhibited GLI1 in DAOY cells but c-MYC in HD-MB03 cells, suggesting cell-type specific BRD4-mediated transcriptional programs. This differential targeting pattern is unexplained but could reveal disti…
gap-pubmed-20260411-065716-540b1556Why does JQ1 show 10-fold differential sensitivity between HD-MB03 and DAOY cell lines?
neuro-oncology openThe abstract reports dramatically different IC50 values (402 nM vs 4220 nM) for JQ1 between two medulloblastoma cell lines, but provides no mechanistic explanation. Understanding this differential sensitivity could reve…
gap-pubmed-20260411-065716-e1171eedWhat explains the concordance between MB-FUS-enriched plasma cfDNA and disease trajectories?
neuro-oncology openThe abstract mentions patient-specific disease courses were concordant with trajectories of MB-FUS-enriched plasma cell-free DNA but provides no mechanistic explanation. Understanding this relationship could reveal biom…
gap-pubmed-20260410-183848-2a7c080aHow does MB-FUS-enhanced drug delivery correlate with actual tissue drug concentrations in glioma?
neuro-oncology resolvedWhile the study demonstrates successful BBB opening via MRI contrast enhancement, it doesn't measure whether this translates to increased temozolomide concentrations in tumor tissue. This pharmacokinetic gap is critical…
gap-pubmed-20260410-183848-3c3140c2What mechanisms determine optimal timing and frequency of MB-FUS treatments for sustained BBB opening?
neuro-oncology openThe study shows MB-FUS can safely open the blood-brain barrier but doesn't explain why treatments were limited to first 3 days of each cycle or how long the opening persists. Understanding optimal dosing schedules could…
gap-pubmed-20260410-183848-d94e9446How does lysosomal stress activation contribute to GBM cell death following SMPD1 inhibition?
neuro-oncology openThe abstract mentions lysosomal stress as a mechanism of GBM killing but doesn't explain how SMPD1 inhibition triggers this pathway. Understanding this connection could reveal additional therapeutic targets and explain…
gap-pubmed-20260410-183839-4ee98302What is the mechanistic link between SMPD1 inhibition, ceramide depletion, and EGFR signaling disruption in GBM?
neuro-oncology openThe abstract identifies SMPD1 as regulating sphingomyelin-to-ceramide conversion and shows fluoxetine inhibits EGFR signaling, but the molecular pathway connecting these events is unclear. This mechanistic gap limits ra…
gap-pubmed-20260410-183839-862be8bfWhy does fluoxetine uniquely inhibit SMPD1 among SSRIs, and what structural features confer this selectivity?
neuro-oncology resolvedThe abstract shows fluoxetine has unique anti-GBM effects not seen with other SSRIs, suggesting SMPD1 inhibition is specific to fluoxetine rather than a class effect. Understanding this selectivity could guide developme…
gap-pubmed-20260410-183839-48c00872Do other chemotherapeutic agents show similar astrocyte-mediated resistance through this pathway?
neuro-oncology openThe study only tested paclitaxel, leaving unknown whether CX43-STAT1 mediated protection is drug-specific or represents a general resistance mechanism. This knowledge gap affects the broader applicability of targeting t…
gap-pubmed-20260410-182038-3c075562How does CX43-mediated intercellular communication specifically activate STAT1 in this context?
neuro-oncology openWhile CX43 inhibition alleviates chemoresistance, the mechanistic link between gap junction communication and STAT1 pathway activation remains unclear. This gap limits understanding of how astrocyte-tumor cell crosstalk…
gap-pubmed-20260410-182038-36166bfeWhat are the downstream molecular targets of CX43-dependent STAT1 signaling that confer chemoresistance?
neuro-oncology openThe study identifies CX43-dependent STAT1 signaling as mediating astrocyte-induced chemoresistance but doesn't reveal the specific downstream effectors or target genes. Understanding these molecular targets is critical…
gap-pubmed-20260410-182038-b5ab7a7fWhy has quercetin's potential in GBM treatment been inadequately explored despite its blood-brain barrier permeability?
neuro-oncology openThe abstract explicitly states that quercetin's potential in GBM has not been adequately explored, despite its known ability to cross the blood-brain barrier and effectiveness against other solid tumors. This represents…
gap-pubmed-20260410-181643-af027a3dWhat are the specific mechanisms by which quercetin overcomes drug resistance in GBM treatment?
neuro-oncology openThe abstract notes that current GBM treatments fail due to drug resistance, and quercetin shows promise, but the mechanistic basis for how quercetin might circumvent resistance pathways is not explained. Understanding t…
gap-pubmed-20260410-181642-e91a4ec1Why do targeted treatments based on molecular alterations have limited efficacy in adult diffuse gliomas?
neuro-oncology openDespite extensive molecular characterization forming the basis of WHO 2021 classification, targeted therapies remain largely ineffective except for BRAF alterations. This contradiction between molecular understanding an…
gap-pubmed-20260410-181407-485c8992Why do some IDH-mutant glioma patients achieve long-term survival (>10-20 years) while others do not?
neuro-oncology openThe abstract notes that combined treatment results in long-term survival for 'some patients' with IDH-mutant tumors, but doesn't explain what distinguishes these exceptional responders. Understanding these mechanisms co…
gap-pubmed-20260410-181407-8caa7e94What determines the specificity of MYCN, MEIS2, and HAND2 complex formation at the IRF2BP2 super-enhancer?
neuro-oncology openThe study identifies a novel transcription factor complex regulating IRF2BP2, but doesn't explain what molecular signals or conditions drive these three factors to specifically associate at this locus. This knowledge ga…
gap-pubmed-20260410-181350-92b19ff1How does AP-1 mechanistically regulate chromatin accessibility to expose IRF2BP2 binding sites?
neuro-oncology openThe abstract states that AP-1 'plays a pivotal role in shaping the chromatin accessibility landscape' to expose IRF2BP2 binding sites, but the specific molecular mechanisms are not explained. Understanding this chromati…
gap-pubmed-20260410-181350-29a98d66